CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100 million in a recent financing round spearheaded by Hygeia Capital. The syndicate of investors includes CAS STAR, Chengdu Biocity Jingchuang Equity Investment Fund, CS Ventures, and other prominent firms. The newly raised capital is earmarked to escalate the clinical development of Leaderna’s innovative small nucleic acid drugs and to bolster its pre-clinical research and talent pool.
Established in 2022, Leaderna Therapeutics has made significant strides with its flagship product, Lipisense, currently in Phase I trials. This groundbreaking treatment is the world’s first for severe hypertriglyceridemia and is on the cusp of expanding its clinical indications to include long-acting treatment for hypertension, with clinical trials expected to commence in the near future.
The successful fundraising round not only underscores Leaderna’s potential in the biotech sector but also highlights the growing interest and confidence of investors in the company’s ability to transform the landscape of nucleic acid therapeutics. With a robust pipeline and a clear vision for the future, Leaderna Therapeutics is poised to make a lasting impact on the treatment of chronic conditions through its cutting-edge drug development strategies.- Flcube.com
